Johnson & Johnson (NYSE: JNJ) completed its $3.05 billion cash acquisition of Halda Therapeutics OpCo, Inc., a clinical-stage biotechnology company ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE